Chardan analyst Geulah Livshits lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $20 from $22 and keeps a Buy rating on the shares. The firm is updating its model following the company’s Q1 results, reiterated guidance on its LX2006 and LX2020 programs, as well as its update on its cash position, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics reports Q1 EPS (99c), consensus (77c)
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- RBC sees Makary interview as potentially positive for biotech stocks
- Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating
- Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc.